Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 16,870 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $2.59, for a total value of $43,693.30. Following the transaction, the director now directly owns 3,798,542 shares of the company’s stock, valued […]